| 0.4804 0.01 (2.21%) | 01-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.61 | 1-year : | 0.68 |
| Resists | First : | 0.52 | Second : | 0.58 |
| Pivot price | 0.5  |
|||
| Supports | First : | 0.41 | Second : | 0.34 |
| MAs | MA(5) : | 0.49 |
MA(20) : | 0.5 |
| MA(100) : | 0.73 |
MA(250) : | 0.62 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1  |
| %K %D | K(14,3) : | 37.2 |
D(3) : | 42.7 |
| RSI | RSI(14): 44 |
|||
| 52-week | High : | 1.32 | Low : | 0.28 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ COSM ] has closed above bottom band by 31.1%. Bollinger Bands are 60.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 27 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.49 - 0.49 | 0.49 - 0.49 |
| Low: | 0.45 - 0.46 | 0.46 - 0.46 |
| Close: | 0.48 - 0.48 | 0.48 - 0.49 |
Cosmos Health Inc. operates as a vertically integrated pharmaceutical company. It offers a proprietary line of branded and generic pharmaceuticals, nutraceuticals, over-the-counter medications, health care and baby products, medical devices, and other products through its distribution channels and an ecommerce marketplace. The company identifies, acquires, develops, and commercializes products that enhance patients' lives and outcomes, as well as has distribution centers in Greece and the United Kingdom; and operates a warehousing facility. It serves wholesale pharmaceutical distributors and independent retail pharmacies. Cosmos Health Inc. was incorporated in 2009 and is headquartered in Chicago, Illinois.
Tue, 20 Jan 2026
Cosmos Health Inc. Reports Continued Growth and Infrastructure Expansion at Cosmofarm in Greece - Quiver Quantitative
Tue, 20 Jan 2026
Greek drug distributor adds 100 pharmacies, builds robots for $40M potential - Stock Titan
Thu, 15 Jan 2026
Cosmos Health CEO Siokas acquires $220,000 in shares - Investing.com
Wed, 14 Jan 2026
Cosmos Health Announces Initiation of Analyst Coverage with $4.50 Valuation by Zacks Small-Cap Research - GlobeNewswire
Wed, 14 Jan 2026
AI research, crypto and $4.50 call put small-cap Cosmos Health on radar - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 37 (M) |
| Shares Float | 25 (M) |
| Held by Insiders | 28.8 (%) |
| Held by Institutions | 8 (%) |
| Shares Short | 146 (K) |
| Shares Short P.Month | 91 (K) |
| EPS | -0.77 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.73 |
| Profit Margin | -31.1 % |
| Operating Margin | -10.7 % |
| Return on Assets (ttm) | -13.1 % |
| Return on Equity (ttm) | -63.9 % |
| Qtrly Rev. Growth | 37.9 % |
| Gross Profit (p.s.) | 0.18 |
| Sales Per Share | 1.6 |
| EBITDA (p.s.) | -0.34 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.63 |
| PEG Ratio | 0 |
| Price to Book value | 0.65 |
| Price to Sales | 0.3 |
| Price to Cash Flow | -2.34 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|